3650 results for «284»
3650 results
FFR and non-hyperaemic pressure ratios
20 May 2026 – From EuroPCR 2026
This session presents contemporary clinical applications of fractional flow reserve (FFR) and non-hyperaemic pressure ratios (NHPR), highlighting real-world impacts of physiology microcatheter-based indices, the interplay between epicardial stenosis and microvascular resistance, post-PCI hyperemia effects on iFR, and machine-learning driven outcome predictions.
Other right-sided and tricuspid valve interventions
20 May 2026 – From EuroPCR 2026
This session focuses on right-sided heart valve interventions, particularly targeting tricuspid valve disease. Topics include clinical outcomes in atrial functional tricuspid regurgitation, management in the context of left-sided valvular disease, treatment approaches for tricuspid valve endocarditis, and advances in transcatheter therapies and device placements.
Insights from real world TAVI practice
20 May 2026 – From EuroPCR 2026
This session presents comprehensive insights from real-world transcatheter aortic valve implantation (TAVI) practice, including sex differences in coronary assessment, the impact of general anesthesia on aortic valve gradients, early rehospitalisation rates, and the management of TAVI in patients with prior hip arthroplasty. Additionally, it explores multinational...
Continual refinement in LAA closure
20 May 2026 – From EuroPCR 2026
This session presents the latest advancements in left atrial appendage closure (LAAC). It covers new risk scoring systems, sex-specific outcome analyses, safety in elderly populations, and comparative data between LAMBRE and WATCHMAN devices from a high-volume center, highlighting continual refinement in LAAC strategies.
New frontiers in coronary disease treatment
21 May 2026 – From EuroPCR 2026
Examine recent advances in coronary disease treatment focusing on drug-eluting stents versus drug-coated balloon strategies. This session presents real-world data on lesion preparation, sex-specific outcomes, physiological disease patterns, and procedural factors influencing PCI success.
Pharmacology without borders, from coronary artherostenosis to radial artery
21 May 2026 – From EuroPCR 2026
This session delves into the expansive role of pharmacology in interventional cardiology, addressing topics ranging from coronary atherostenosis to radial artery management. Key discussions include the real-world efficacy and safety of intravenous cangrelor-assisted PCI in chronic coronary syndromes, comparative analysis of intra-arterial verapamil versus placebo for...
Focus on heart failure: from acute to chronic
21 May 2026 – From EuroPCR 2026
This comprehensive session delves into the spectrum of heart failure management, from acute presentations to chronic conditions. Key topics include the cardio-hepatic syndrome and right ventricular dysfunction in HFmrEF, prognostic implications of heart failure etiologies, and innovative approaches such as AI-assisted echocardiography for early detection of...
Strategies to enhance bifurcation PCI outcomes
21 May 2026 – From EuroPCR 2026
This session addresses strategies to optimize outcomes in coronary bifurcation PCI. It evaluates the impact of cutting and scoring balloons versus non-compliant balloons on stent expansion, predictors of target vessel revascularization using the POKI technique, and compares stent and non-stent approaches in side branch myocardial infarction...
Coronary OCT and CMR imaging to determine sex differences in underlying causes of myocardial infarction with no obstructive coronary arteries
29 Mar 2026
Nicola Ryan provides her take on the trial evaluating multi-modality imaging to determine underlying causes of MINOCA in women and men. The trial results were presented by Harmony R. Reynolds at ACC.26 in New Orleans and simultaneously published in Circulation.

Author
ALL-RISE: A large-scale, global randomized trial of coronary physiology derived from conventional angiography compared with an invasive pressure wire-based approach to guide PCI
28 Mar 2026
Mirvat Al Asnag provides her take on the ALL-RISE randomised trial presented by Ajay J. Kirtane at ACC.26 in New Orleans.

Author